Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8041093 | 0.73 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2PRSS1CTSG | |
| SCHEMBL7145599 | 0.73 | KIF11 (0.38) | CES1ALDH1A1 | |
| SCHEMBL3601229 | 0.71 | KMT2A (0.68) | RAB9ANPC1SMN1; SMN2PRSS1CTSG | |
| SCHEMBL8506869 | 0.71 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2HPGDGAA | |
| SCHEMBL8507006 | 0.71 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2HPGDGAA | |
| SCHEMBL3377096 | 0.71 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2HPGDGAA | |
| SCHEMBL7561649 | 0.70 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2PRSS1CTSG | |
| SCHEMBL18680060 | 0.70 | SMN1; SMN2 (0.56) | RAB9ANPC1SMN1; SMN2PRSS1CTSG | |
| SCHEMBL7121699 | 0.70 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HPGDGAA | |
| SCHEMBL255251 | 0.69 | GAA (0.76) | RAB9ANPC1SMN1; SMN2HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | disclosed |
| US-6448373-B1 | INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0739351-B1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | RAB9A 4371/4885NPC1 4306/4885SMN1; SMN2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.